Contact Supplier

Contact Supplier

To get in touch with Evercyte GmbH, simply fill out the form below.

    Subscribe to Supplier

    Subscribe to Supplier


    Evercyte showcasing extracellular vesicle capabilities at GSEV/ASEV Autumn Meeting 2022

    news-releasesEvercyte GmbH
    October 19th 2022

    Vienna, Austria: – Innovative biotech manufacturer Evercyte will highlight its advanced capabilities in producing clinic grade extracellular vesicles (EVs) when it attends the upcoming joint Autumn Meeting of the German and Austrian Societies for Extracellular Vesicles (GSEV & ASEV) in Salzburg.

    As a noted ASEV member, Evercyte is always a prominent presence at ASEV/GSEV meetings and this year will present a poster on its ‘Standardized cell factories for production of biologically active, clinical-grade MSC-EVs’

    Clinically effective human MSc EVs

    The presentation will highlight the clinical effectiveness of EV production cell lines based on differentiated human tissues and organs such as adipocyte derived mesenchymal stromal cells (ASC/TERT300), bone marrow mesenchymal stromal cells (BM-MSC/TERT292), placenta-derived MSCs (CP-MSC/TERT308), and MSCs derived from reflected (RA-MSC/TERT308) and placental (P-MSC/TERT308) amniotic membrane.

    Evercyte’s will also use the meeting to discuss applications of its EV characterization and in vitro biological activity testing services, such as enrichment of EVs from cell culture supernatant, characterization of EVs, and potency assays.

    Scientific focus

    Evercyte will be represented at the Salzburg meeting by Dr. Giulia Corso, its Head of Science and Business Communication, who will take part in networking sessions to discuss ways to take advantage of Evercyte’s EV products, including ready-to-use EVs from different human cell cultures, EV production cell lines, and testing services

    “I am greatly looking forward to the chance to meet colleagues in Salzburg for this wonderful event, which has become an annual fixture in our calendar with its rigorous scientific focus and forward-looking ethos,” said Dr. Corso.

    About Evercyte GmbH

    Evercyte is the leading provider of immortalized human primary-like cells (‘telomerized cells’) as well as novel production cell lines for extracellular vesicles and is the partner of choice for innovative cell-based assays in the field of pharma, biotech, or cosmetic industries.

    The core technology used for the establishment of these highly relevant human cell lines relies on the reactivation of the human telomerase enzyme. Besides customer-tailored cell line development as a one-stop shop, Evercyte is steadily expanding its catalog of readily available cell lines for the production of extracellular vesicles from mesenchymal stem cells using different tissues including adipose tissue, bone marrow, placenta, amnion or dental pulp.

    By providing native extracellular vesicles from mesenchymal stem cells and targeting extracellular vesicles Evercyte will make a significant contribution to the development of new therapeutic approaches. Additionally, Evercyte will promote its platform technology for the generation of recombinant EVs for e.g. tissue targeting and drug targeting.

    Founded in 2011, the Vienna-based company successfully pioneered the development of tools and know-how necessary for the establishment of standardized high-throughput in-vitro bioassays as well as relevant cell models and cell factories.

    Learn more at:

    About GSEV/ASEV Autumn Meeting 2022

    The German Society for Extracellular Vesicles (GSEV) staged its first Autumn Meeting in partnership with the Austrian Society for Extracellular Vesicles (ASEV) in 2018.

    The joint meeting provides a networking event, scientific conference and a forum for young researchers specializing in extracellular vesicle studies to share their knowledge.

    The 4th GSEV/ASEV Autumn Meeting, is a two-day event opening October 28 at the Paracelsus Medical Private University in Salzburg, Austria. The conference is themed ‘Small New World’ with a scientific program strongly focused on the sourcing, tracing and drug delivery potential of ultra-small EV nanovesicles.’

    The event is jointly organized by GSEV, ASEV and their co-owned EVTT Technology Transfer Center. Further information at:


    Click on Evercyte EV cell factories  for further information.
    Click on Evercyte EV cell services  for further information.

    Evercyte showcasing extracellular vesicle capabilities at GSEV/ASEV Autumn Meeting 2022

    Contact Evercyte GmbH

    Simply fill out the form below to contact Evercyte GmbH now.

    Send Evercyte GmbH a Message